No Data
No Data
No Data
No Data
No Data
Mineralys Therapeutics Board Member Announces Departure
TipRanksApr 4 20:12
Goldman Starts Mineralys at Buy, Cites Upcoming Drug Data
Seeking AlphaApr 3 02:37
QuidelOrtho Stock Falls 11% on Savanna PVP4+ Assay Update
Seeking AlphaApr 3 02:01
Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30
Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $30.
BenzingaApr 2 19:10
Mineralys Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 126.93% Goldman Sachs → $30 Initiates Coverage On → Buy 08/08/2023 179.88% Credit Suisse $38 →
BenzingaApr 2 19:10
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 22 22:51
No Data
No Data